Solid biosciences inc. (SLDB)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-114,335

-117,223

-107,283

-97,048

-88,503

-74,798

-67,364

-61,849

-55,180

-53,178

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of (discount)/premium on available-for-sale securities

152

279

284

291

243

90

40

-9

-104

-206

0

0

0

Equity-based compensation expense

13,811

14,207

12,833

11,238

8,636

5,955

4,748

3,741

2,919

5,330

0

0

0

Depreciation expense

3,254

2,824

2,499

2,280

1,935

1,566

1,308

873

624

448

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current and non-current assets

-3,988

-4,486

4,264

8,807

4,996

4,930

2,089

1,215

10

-815

0

0

0

Accounts payable

-2,196

3,779

-1,495

1,884

410

-1,610

-807

1,786

393

1,579

0

0

0

Accrued expenses and other current and non-current liabilities

-433

-510

5,112

1,001

2,982

2,883

1,176

164

1,409

2,035

0

0

0

Net cash used in operating activities

-96,061

-92,714

-92,873

-88,922

-78,952

-70,197

-62,775

-56,924

-50,200

-43,224

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

3,115

4,387

5,179

6,651

8,728

7,776

6,665

6,206

3,029

2,276

0

0

0

Proceeds from sale and maturities of available-for-sale securities

-56,975

-60,399

-62,649

-55,244

-27,750

-25,335

-24,856

-23,633

-32,920

-31,621

0

0

0

Purchases of marketable investments

0

-

-

-

0

-

-

-

-

-

-

-

-

Purchases of available-for-sale securities

-

-

-

-

-

44,321

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

37,379

24,516

397

-4,963

-31,596

-26,762

-8,307

-14,226

1,875

10,448

0

0

0

Cash flows from financing activities:
Proceeds from issuance of preferred units

-

-

-

-

-

-

-

-

-

-

0

0

0

Payment of offering costs

-

-

-

-

-

2,168

3,413

4,356

4,221

2,424

0

0

0

Proceeds from initial public offering of common stock, net of commissions and underwriting discounts

-

-

-

-

-

133,688

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

131,507

185,277

184,334

183,969

77,078

0

0

0

Net decrease in cash, cash equivalents and restricted cash

-807

-10,323

-34,327

-93,898

-110,754

34,548

0

0

0

-

-

-

-

Net increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of non-cash investing and financing activities:
Operating lease liabilities arising from obtaining right-of-use asset

-

-

0

0

0

-

-

-

-

-

-

-

-

Accretion of preferred units to redemption value

-

-

-

-

-

-

-

-

-

959

0

0

0

Redemption of preferred units

-

-

-

-

-

-

-

-

-

15,685

0

0

0

Redemption of redeemable interest from non-controlling interest in Solid GT

-

-

-

-

-

-

-

-

-

1,925

0

0

0

Deferred offering costs included in accounts payable

-

-

-

-

-

-

-

-

0

-

-

-

0

Offering costs included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

0

Property and equipment included in accounts payable and accruals

-498

490

490

632

516

952

567

661

1,728

265

0

0

0

Series 1 Senior Preferred Units [Member]
Conversion of units into shares of common stock

-

-

-

-

-

25,000

0

0

0

-

-

-

-

Series 2 Senior Preferred Units [Member]
Conversion of units into shares of common stock

-

-

-

-

-

55,002

0

0

0

-

-

-

-

Junior Preferred Units [Member]
Conversion of units into shares of common stock

-

-

-

-

-

44,177

0

0

0

-

-

-

-

Series A, B, C and D Common Units [Member]
Conversion of units into shares of common stock

-

-

-

-

-

65,180

0

0

0

-

-

-

-